Moderate to severe persistent allergic rhinitis Ear, Nose and Throat Allergic rhinitis, unspecified
Conditions
Interventions
Current interventions as of 17/11/2020:
Eligible patients will be randomly assigned into treatment group or control group. The method of randomisation is central competitive randomization. The researc
twice a week in the 5th to 6th weeks.
The control group will receive fluticasone propionate nasal spray 100µg per daily for 6 weeks.
The treatment time was 6 weeks. After the treatment, the patients
twice a week in the 5th to 6th weeks.
The control group will
Sponsors
China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18 to 65 years old 2. Diagnosed with persistent allergic rhinitis according to the diagnosis of Allergic Rhinitis and its Impaction Asthma, ARIA (WHO, 2008) 3. Meet the criteria for moderate to severe allergic rhinitis: the symptoms have a significant impact on the quality of life. The overall score of =6 on the Reflective Total Nasal Symptom Score (rTNSS) 4. Presence of nasal symptoms for 2 successive years 5. Agrees to participate in the study willingly and voluntarily and signs the informed consent form
Exclusion criteria
Exclusion criteria: 1. Presence of rhinosinusitis, respiratory diseases, acute paranasal sinusitis, or other systemic diseases that may affect allergic rhinitis 2. Patients are allergic to the fumes from moxibustion 3. Has taken nasal/oral decongestants, nasal/oral antihistamines, mast cell membrane stabilizer, glucocorticoid or antileukotrienes within the past 2 weeks; use of drugs the researchers believe are inappropriate 4. Patients who have received specific immunotherapy or systemic hormone therapy within the last year 5. Patients have received the following treatment measures for allergic rhinitis within the past month: acupuncture, moxibustion, inhalation therapy of Chinese medicine and other physical therapy within the scope of traditional medicine, and external treatment of western medicine or other therapies 6. Patient with severe cardiovascular diseases and endocrine diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of allergic rhinitis symptoms measured using Reflective Total Nasal Symptom Score (rTNSS) at baseline and the end of treatment (6 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Severity of allergic rhinitis symptoms measured using the Reflective Total Nasal Symptom Score (rTNSS) at baseline, weekly after treatment, week 6 and follow-up months 1, 3, 6 2. Severity of non-nasal symptoms measured using Total Non-Nasal Symptom Score (TNNSS) at baseline, weekly after treatment, week 6 and follow-up months 1, 3, 6 3. Severity of ocular symptoms measured using the reflective total ocular symptom score (rTOSS) at baseline, weekly after treatment, week 6 and follow-up months 1, 3, 6 4. Health-related quality of life measured using RQLQ(S) at baseline, week 6 and follow-up months 1, 3, 6 5. Rescue medication use measured using a 3-point scale: 1- nasal/oral antihistamines, 2- nasal glucocorticoids, 3- oral glucocorticoids at baseline, week 6 and follow-up months 1, 3, 6 6. Rhinitis control assessed using the Rhinitis Control Assessment Test (RCAT) at baseline, weeks 4 and 6, and follow-up months 1, 3, 6 | — |
Countries
China
Outcome results
None listed